Item does not contain fulltextWomen with a BRCA1/2 mutation have a high genetic risk of developing breast and ovarian cancer. They face the difficult choice between screening and prophylactic surgery for the breasts and ovaries. We have developed a shared decision making program to prepare these women for decision making. The shared decision making program consisted of two decision aids. The decision aids have been developed as adjuncts to standard genetic counselling and were evaluated in a randomized trial. The study included both women affected and unaffected with cancer testing for a BRCA1/2 mutation. The first decision aid consisted of a brochure and video providing information on screening and prophylactic surgery and their consequenc...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...
Women with a BRCA1/2 mutation have a high genetic risk of developing breast and ovarian cancer. They...
Background: Women with BRCA1/2 mutations have a higher risk of developing breast and ovarian cancer ...
Background Women with pathogenic BRCA1 and BRCA2 mutations possess a high risk of d...
Purpose To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 mutation carriers who h...
Background: Female BRCA1 and BRCA2 mutation carriers have an increased lifetime risk of developing b...
PURPOSE: To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 mutation carriers who ...
The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being...
The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being...
Women with a suspected genetic predisposition for breast cancer face the difficult choice between pa...
Purpose To measure the effectiveness of a tailored decision aid (DA) designed to help women make inf...
Women with a suspected BRCA1/2-mutation may choose between two management options: breast cancer scr...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...
Women with a BRCA1/2 mutation have a high genetic risk of developing breast and ovarian cancer. They...
Background: Women with BRCA1/2 mutations have a higher risk of developing breast and ovarian cancer ...
Background Women with pathogenic BRCA1 and BRCA2 mutations possess a high risk of d...
Purpose To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 mutation carriers who h...
Background: Female BRCA1 and BRCA2 mutation carriers have an increased lifetime risk of developing b...
PURPOSE: To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 mutation carriers who ...
The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being...
The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being...
Women with a suspected genetic predisposition for breast cancer face the difficult choice between pa...
Purpose To measure the effectiveness of a tailored decision aid (DA) designed to help women make inf...
Women with a suspected BRCA1/2-mutation may choose between two management options: breast cancer scr...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...